Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

2026-02-18 - 13:43

VANCOUVER, British Columbia & GRAPEVINE, Texas -- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.” Read More